IP Library Granted Patent US 11,752,175
Granted Patent B2
US 11,752,175 · App. 16/578,320 · Granted Sep 12, 2023

Compositions and methods for glaucoma

Inventors: John T. G. Pena (New York, NY); James Murray Mitchell (Danville, CA); Harmon Lawrence Remmel (New York, NY)
Assignee: Cornell University
A61K35/30A61K9/1271C12N5/0621C12N2509/00C12N2521/00C12N2525/00C12N2527/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,752,175
App. No.
16/578,320
Granted
Sep 12, 2023
Kind
B2
Abstract

This invention relates to methods and compositions for detecting, identifying and treating glaucoma diseases. More particularly, this invention discloses compositions and methods for affecting intraocular pressure and increasing ocular outflows in glaucoma. Compositions and methods provided include purified and synthesized extracellular vesicle complexes from glaucoma ocular humor for use in methods and devices for detecting, characterizing and treating glaucoma diseases along with active agents. The presence of extracellular vesicle complexes in glaucoma can also be used as a biomarker.

Claims (9)

1. A composition, consisting of extracellular vesicle aggregate complexes isolated from a glaucoma ocular humor, wherein the extracellular vesicle aggregate complexes are present in native glaucoma ocular humor, and wherein the extracellular aggregate complexes have at least 10 extracellular vesicles.

2. The composition of claim 1 , wherein the composition is isolated from animal or clinical sources.

3. The composition of claim 1 , wherein the extracellular vesicle aggregate complexes comprise one or more of exomeres, exosomes, multivesicular bodies, intraluminal vesicles (ILVs), multivesicular endosomes (MVEs), oncosomes, micro-vesicles, apoptotic bodies, or vesicles originating from endosome or plasma membranes.

4. The composition of claim 1 , wherein the extracellular vesicle aggregate complexes have a size from 1,000 nm to 15,000 nm.

5. The composition of claim 1 , wherein the extracellular vesicle aggregate complexes have a size from 2,000 nm to 10,000 nm.

6. The composition of claim 1 , wherein the extracellular vesicle aggregate complexes have a size from 2,000 nm to 5,000 nm.

7. The composition of claim 1 , wherein the extracellular vesicle aggregate complexes have a size from 360 nm to 3,000 nm.

8. The composition of claim 1 , wherein the extracellular vesicle aggregate complexes have a size from 360 nm to 1,000 nm.

9. The composition of claim 1 , wherein at least 50% of the extracellular vesicle aggregate complexes have a diameter from 360 to 21,000 nanometers.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2021
From: PENA, JOHN T. G.
To: CORNELL UNIVERSITY
Reel/Frame 056314/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2021
From: MITCHELL, JAMES MURRAY
To: AUFBAU MEDICAL INNOVATIONS LIMITED
Reel/Frame 056314/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2021
From: REMMEL, HARMON LAWRENCE
To: AUFBAU MEDICAL INNOVATIONS LIMITED
Reel/Frame 056314/0248 →
Continuity (2)
Provisional Application 62734699 · Sep 21, 2018
Related Publication 20200121724A1 · Apr 23, 2020